文献速递淋巴瘤

纳武利尤单抗联合多柔比星、长春碱和达卡巴嗪治疗早期不良霍奇金淋巴瘤:德国霍奇金研究组随机II期NIVAHL试验最终分析

Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
PubMed 文献 · J Clin Oncol · 2022-12-12

NIVAHL试验在109例早期不良经典霍奇金淋巴瘤患者中比较两种纳武利尤单抗联合多柔比星、长春碱和达卡巴嗪方案后行30 Gy受累部位放疗。中位随访41个月,两组总生存率均为100%,无进展生存率分别为98%和100%,甲状腺功能减退需长期用药者占15%,未发生第二原发恶性肿瘤。

要点

  • 中位随访41个月,两组总生存率均为100%,无进展生存率分别为98%和100%。
  • 甲状腺功能减退需长期用药者占15%,其中87%为女性。
  • 未发生第二原发恶性肿瘤,末次随访时无患者需糖皮质激素治疗。

核心结论

  • 该预先计划的最终分析证实,纳武利尤单抗联合多柔比星、长春碱和达卡巴嗪方案治疗早期不良经典霍奇金淋巴瘤具有突出疗效和相对良好的安全性。

研究设计与样本

  • 研究者发起的随机II期NIVAHL试验纳入109例早期不良经典霍奇金淋巴瘤患者,比较两种四周期纳武利尤单抗联合多柔比星、长春碱和达卡巴嗪方案后行30 Gy受累部位放疗。

主要发现

  • 自主要分析以来未观察到生存事件,中位随访41个月时两组总生存率均为100%。
  • 无进展生存率在序贯组为98%,在同步组为100%。
  • 末次随访时,第一秒用力呼气量均值为95.5%(标准差12.7%),经血红蛋白校正的一氧化碳弥散量均值为82.8%(标准差15.4%),95%患者左心室射血分数在正常范围。
  • 甲状腺功能减退需长期用药者占15%,其中87%为女性。
  • 未发生第二原发恶性肿瘤,末次随访时无患者需糖皮质激素治疗,欧洲癌症研究与治疗组织生活质量问卷C30报告的标准化总体生活质量评分随时间改善。

关键数值与推荐

  • 四周期纳武利尤单抗联合多柔比星、长春碱和达卡巴嗪后行30 Gy受累部位放疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.In the investigator-sponsored randomized phase II NIVAHL trial for early-stage unfavorable classical Hodgkin lymphoma (HL), two schedules of four cycles of nivolumab, doxorubicin, vinblastine, and dacarbazine followed by 30 Gy involved-site radiotherapy resulted in high complete remission rates and an unprecedented 1-year progression-free survival in 109 patients. In this article, we report the preplanned final analysis conducted three years after the registration of the last patient including long-term safety results. No survival events were observed since the primary analysis, and after a median follow-up (FU) of 41 months, the overall survival was 100% in both treatment groups. The progression-free survival was 98% and 100% in the sequential and concomitant nivolumab, doxorubicin, vinblastine, and dacarbazine treatment groups, respectively. At last FU, the mean forced expiratory pressure in one second was 95.5% (standard deviation 12.7%), the mean diffusion capacity for carbon monoxide adjusted for hemoglobin was 82.8% (standard deviation 15.4%), and the left ventricular ejection fraction was in the normal range in 95% of patients. Hypothyroidism requiring long-term medication occurred in 15% of patients, who were nearly exclusively female (87%). No second primary malignancies occurred, and no patient required corticosteroid treatment at last FU. Patient-reported normalized global quality-of-life score measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 improved over time. This preplanned FU analysis of the largest anti-programmed death protein 1 HL first-line trial to date confirms the outstanding efficacy and relatively favorable safety profile of this therapeutic approach.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bröckelmann PJ, Bühnen I, Meissner J, et al. Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial. J Clin Oncol. 2022. PMID: 36508302. doi:10.1200/JCO.22.02355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。